Published in World Allergy Organ J on February 15, 2010
Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol (2007) 15.45
Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet (2002) 8.57
Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med (1997) 8.48
Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med (2005) 7.61
Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med (2007) 5.31
Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med (2004) 4.37
British Guideline on the Management of Asthma. Thorax (2008) 4.10
Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet (2006) 3.93
Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J (2006) 3.09
Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med (2006) 2.08
Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med (1999) 1.96
Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA (2004) 1.84
Effect of budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract (2007) 1.64
Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate. Respirology (2004) 1.49
Scientific rationale for using a single inhaler for asthma control. Eur Respir J (2007) 1.41
Clinical Decisions. Treatment of mild persistent asthma. N Engl J Med (2007) 1.40
Structural changes in airway diseases: characteristics, mechanisms, consequences, and pharmacologic modulation. Chest (2006) 1.38
Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthma. Allergy (2007) 1.36
Tailored interventions based on sputum eosinophils versus clinical symptoms for asthma in children and adults. Cochrane Database Syst Rev (2007) 1.29
Quadrupling the dose of inhaled corticosteroid to prevent asthma exacerbations: a randomized, double-blind, placebo-controlled, parallel-group clinical trial. Am J Respir Crit Care Med (2009) 1.20
Long-acting beta2-agonists in asthma: not so SMART? Drug Saf (2006) 1.20
Strategy aimed at reduction of sputum eosinophils decreases exacerbation rate in patients with asthma. J Int Med Res (2006) 1.14
Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J (2006) 1.13
Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther (2005) 1.12
Additive anti-inflammatory effect of formoterol and budesonide on human lung fibroblasts. Thorax (2002) 1.02
Mast cell tryptase release and asthmatic responses to allergen increase with regular use of salbutamol. J Allergy Clin Immunol (2000) 0.96
Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help? Br J Gen Pract (2008) 0.93
Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy (2007) 0.90
Systematic review and meta-analysis of budesonide/formoterol in a single inhaler. Curr Med Res Opin (2007) 0.89
Lung myofibroblasts as targets of salmeterol and fluticasone propionate: inhibition of alpha-SMA and NF-kappaB. Int Immunol (2005) 0.88
Anti-proliferative and anti-remodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchial fibroblasts. Allergy (2007) 0.88
Novel anti-inflammatory effects of the inhaled corticosteroid fluticasone propionate during lung myofibroblastic differentiation. J Immunol (2001) 0.83
Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy (2005) 0.83
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J (2013) 8.39
Pathological features and inhaled corticosteroid response of eosinophilic and non-eosinophilic asthma. Thorax (2007) 2.37
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J (2012) 2.11
Airway hyperresponsiveness is dissociated from airway wall structural remodeling. J Allergy Clin Immunol (2008) 1.76
Mast cells promote airway smooth muscle cell differentiation via autocrine up-regulation of TGF-beta 1. J Immunol (2008) 1.34
Vascular remodeling is a feature of asthma and nonasthmatic eosinophilic bronchitis. J Allergy Clin Immunol (2007) 1.17
TNF-alpha in asthma. Curr Opin Pharmacol (2007) 1.04
Airway wall expression of OX40/OX40L and interleukin-4 in asthma. Chest (2010) 0.96
IL-13 expression by blood T cells and not eosinophils is increased in asthma compared to non-asthmatic eosinophilic bronchitis. BMC Pulm Med (2009) 0.85
Mast cell fibroblastoid differentiation mediated by airway smooth muscle in asthma. J Immunol (2010) 0.85
Airway smooth muscle hypercontractility in asthma. J Allergy (Cairo) (2013) 0.83
Cytokines and cytokine-specific therapy in asthma. Adv Clin Chem (2012) 0.82
Magic bullets: the new goal for asthma. Am J Respir Crit Care Med (2009) 0.82
TNF-alpha antagonism in severe asthma? Recent Pat Inflamm Allergy Drug Discov (2010) 0.81
Can inhaled corticosteroids prevent asthma exacerbations? Curr Opin Pulm Med (2011) 0.75